Back to News
Market Impact: 0.25
Immunocore announces achievement of target enrollment in registrational TEBE-AM trial with KIMMTRAK® (tebentafusp) in previously treated advanced melanoma
Source: GlobeNewswire
Healthcare & BiotechCompany Fundamentals
Immunocore reached its target enrollment for the registrational TEBE-AM trial of KIMMTRAK (tebentafusp) in previously treated advanced melanoma. The milestone advances the drug’s potential label expansion and reduces clinical-trial execution risk, though no efficacy or safety data were disclosed.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
IMCR0.72
More News
- What investors need to know about Alphabet's stock-busting earnings report
- Our next steps for Alphabet stock after earnings disappoint at nearly every turn
- Fortinet’s stock is taking a dive after earnings. Here’s why.
- Wendy's shares jump 15% as Nelson Peltz's Trian offers $1.4 billion to buy burger chain
- Microsoft's Big Bets on AI Start to Pay Off
- Google's Gemini 4 Carbon looks like a diamond in the rough